Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 7:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 3,620 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: NIDDM Clear all
Completed Not applicable Interventional Results available

Diabetes Care for Breast Cancer Patients

NCT05565534
View directory record Official record
Conditions
Breast Cancer, PreDiabetes, Type 2 Diabetes
Interventions
Nurse-practitioner led intervention
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Brooklyn, New York • Flushing, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 27, 2026, 7:42 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors

NCT02019264
View directory record Official record
Conditions
Cardiovascular Disease, High Cardiovascular Risk, Obesity, Overweight, Type 2 Diabetes
Interventions
Lorcaserin hydrochloride, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
40 Years and older
Enrollment
14,673 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
373
States / cities
Alexander City, Alabama • Athens, Alabama • Birmingham, Alabama + 283 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Oct 27, 2026, 7:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Trial to Assess Steviol Glycosides on Acute Appetite Hormone Release

NCT05287906
View directory record Official record
Conditions
Overweight and Obesity, Type 2 Diabetes Mellitus
Interventions
Water, Glucose, Steviol Glycosides, Steviol Glycosides plus glucose, Rebaudioside A
Other
Lead sponsor
Midwest Center for Metabolic and Cardiovascular Research
Other
Eligibility
18 Years to 50 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
3
States / cities
Miami Gardens, Florida • Naples, Florida • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 27, 2026, 7:42 AM EDT
Terminated Phase 3 Interventional

Inhaled Technosphere Insulin in Subjects With Diabetes Mellitus and Asthma

NCT00332826
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Asthma
Interventions
Technosphere Insulin
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
25
States / cities
Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated May 4, 2012 · Synced Oct 27, 2026, 7:42 AM EDT
Completed Phase 1 Interventional

To Evaluate 24-hr Glucose After OD vs BD AZD1656

NCT00819884
View directory record Official record
Conditions
Type II Diabetes
Interventions
AZD1656
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
30 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2009 · Synced Oct 27, 2026, 7:42 AM EDT
Completed Phase 3 Interventional Results available

A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

NCT04255433
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Tirzepatide, Dulaglutide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
40 Years and older
Enrollment
13,299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
121
States / cities
Birmingham, Alabama • Concord, California • Covina, California + 106 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 27, 2026, 7:42 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD

NCT02547935
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, CKD and Albuminuria
Interventions
Dapagliflozin 10 mg, Saxagliptin 2.5 mg, Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
37
States / cities
Peoria, Arizona • Chula Vista, California • Concord, California + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Oct 27, 2026, 7:42 AM EDT
Completed Phase 2 Interventional

Safety and Tolerability Study of MBX-2044 in Patients With Type 2 Diabetes

NCT00422487
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
MBX-2044, Placebo for MBX-2044
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2015 · Synced Oct 27, 2026, 7:42 AM EDT
Active, not recruiting Phase 1 Interventional

Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D

NCT07399678
View directory record Official record
Conditions
Overweight or Obese Adults, Overweight or Obese, Type 2 Diabetes
Interventions
ALV-100, Placebo
Drug
Lead sponsor
Alveus Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Miami, Florida • Columbus, Ohio • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 27, 2026, 7:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Orally Ingesting Branched Chained Amino Acids on Delayed Onset Muscle Soreness in Diabetic Patients

NCT01211717
View directory record Official record
Conditions
Type 2 Diabetes, Healthy Individuals
Interventions
Branched Chained Amino Acids, Cellulose Placebo mix
Dietary Supplement · Other
Lead sponsor
Loma Linda University
Other
Eligibility
20 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2011 · Synced Oct 27, 2026, 7:42 AM EDT
Withdrawn Phase 3 Interventional

A Study of Insulin Peglispro (LY2605541) in Participants With Type 2 Diabetes Mellitus

NCT02106364
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin Peglispro, Insulin Glargine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
10
States / cities
Birmingham, Alabama • Zephyrhills, Florida • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2016 · Synced Oct 27, 2026, 7:42 AM EDT
Completed Not applicable Interventional

Cyber Disease Management: Using the World Wide Web to Share the Medical Record With Patients at Home

NCT00194506
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Internet co-management module
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 14, 2006 · Synced Oct 27, 2026, 7:42 AM EDT
Completed Not applicable Interventional

Cardiovascular Disease Education and Problem-Solving Training in People With Type 2 Diabetes

NCT00964587
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Education + Problem-Solving Training Self-Study, Education + Group Problem-Solving Training, Education + Individual Problem-Solving Training, Usual Care
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
25 Years and older
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Oct 27, 2026, 7:42 AM EDT
Terminated Not applicable Interventional

Nutraceutical Citrulline in Pregnancy

NCT02772887
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
L-Citrulline, Placebo
Dietary Supplement · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
14 Years to 40 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 30, 2019 · Synced Oct 27, 2026, 7:42 AM EDT
Completed Phase 3 Interventional Results available

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone

NCT00763815
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Lixisenatide (AVE0010), Placebo, Pen auto-injector, Pioglitazone, Metformin
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
85
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Oct 27, 2026, 7:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Nutritional Products in Subjects With Type 2 Diabetes

NCT02923960
View directory record Official record
Conditions
Diabetes
Interventions
Standard ONS, Diabetes specific ONS 1, Diabetes specific ONS 2
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
18 Years to 70 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Chicago, Illinois • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 27, 2026, 7:42 AM EDT
Withdrawn Not applicable Interventional

Reversibility of Brain Glucose Transport and Metabolism in T2DM: an Intervention Study

NCT04283617
View directory record Official record
Conditions
Diabete Type 2
Interventions
Intensification of insulin regimen/Nutrition
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 16, 2024 · Synced Oct 27, 2026, 7:42 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes

NCT00212290
View directory record Official record
Conditions
Insulin Resistance, Type 2 Diabetes Mellitus
Interventions
pioglitazone, nateglinide, placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
55 Years and older
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2006
U.S. locations
2
States / cities
Seattle, Washington • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Feb 15, 2010 · Synced Oct 27, 2026, 7:42 AM EDT
Completed Phase 4 Interventional

Study of Effectiveness of Liraglutide Added to High Dose Insulin in Type II Diabetics

NCT01654120
View directory record Official record
Conditions
Diabetes Mellitus, Type II
Interventions
Liraglutide, Insulin
Drug
Lead sponsor
Mountain Diabetes and Endocrine Center
Other
Eligibility
18 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Asheville, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Oct 27, 2026, 7:42 AM EDT
Not listed No phase listed Observational

Feasibility Trial of the Bios Device for Continuous Glucose Monitoring

NCT04226846
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
Not listed
Lead sponsor
GraphWear Technologies Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 27, 2026, 7:42 AM EDT
Withdrawn Phase 4 Interventional

Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes.

NCT03640221
View directory record Official record
Conditions
Hypertension, Diabetes Mellitus, Type 2
Interventions
Ertugliflozin, Hydrochlorothiazide 12.5mg, Microneurography, SKNA recordings, Static Handgrip, Post-handgrip forearm vascular occlusion, Testing of the Arterial Baroreflex Function
Drug · Device · Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
35 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 27, 2026, 7:42 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Fitness and Sleep in People With Family History of Type 2 Diabetes.

NCT00721084
View directory record Official record
Conditions
Sleep, Physical Fitness, Type 2 Diabetes
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
21 Years to 40 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 27, 2026, 7:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Mobile Diabetes Prevention for Hispanics Living in Rural Areas

NCT05856149
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Mobile Diabetes Prevention Program
Behavioral
Lead sponsor
ISA Associates, Inc.
Other
Eligibility
18 Years to 99 Years
Enrollment
179 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Alice, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 27, 2026, 7:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Specialized Diet for the Unique Metabolic Characteristics of Peripubertal African American Girls

NCT00718874
View directory record Official record
Conditions
Obesity, Type 2 Diabetes
Interventions
Dietary
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
9 Years to 15 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 27, 2026, 7:42 AM EDT